Dosage of ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis

Therapeutic Drug Monitoring

Volumn 24, Issue 6, 2002, Pages 701-708

  Bruchfeld, Annette ^a   Lindahl, Karin ^b   Schvarcz, Robert ^b   Ståhle, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Body weight; Hepatitis C; Population pharmacokinetics; Renal function; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; CREATININE;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEPATITIS C; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; ALGORITHM; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; KIDNEY FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; ULTRAVIOLET SPECTROPHOTOMETRY;

ADULT; ALGORITHMS; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DRUG MONITORING; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS C; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; RIBAVIRIN; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0036890967     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200212000-00004     Document Type: Article

References (13)

1. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: Alpha interferon and ribavirin. Hepatology 1997;26(suppl 1):108S-11S.
2. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks alpha2b plus ribavirin treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
3. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment of chronic hepatitis C. N Engl J Med 1998;339:1485-92.
4. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;19(suppl 1):17-24.
5. Trepo C, Bailly F, Bizollon T. Treatment of chronic hepatitis C: Another therapeutic option. Nephrol Dial Transplant 1996;11: 62-4.
6. Kramer TH, Gaar GG, Ray CG, et al. Hemodialysis clearance of intravenously administered ribavirin. Antimicrob Agents Chemother 1990;43:489-90.
7. Svensson J-O, Bruchfeld A, Schvarcz R, et al. Determination of ribavirin in serum using highly selective solid-phase extraction and high performance liquid chromatography. Ther Drug Monit 2000; 22:215-8.
8. Bruchfeld A, Ståhle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - A pilot study. J Viral Hepat 2001;8:287-92.
9. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000;22:555-65.
10. Rowland M, Tozer T. Clinical Pharmacokinetics: Concepts and Applications. 3rd Ed. Williams & Wilkins, 1995:258.
11. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31.
12. Granerus G, Aurell M. Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest 1981;41:611-6.
13. Duncan L, Heathcote J, Djurdjev O, et al. Screening for renal disease using serum creatinine: Who are we missing? Nephrol Dial Transplant 2001;16:1042-6.